Exploring the Impact of Anti-PD-1 and Anti-PD-L1 Agents in Merkel Cell Carcinoma

August 17, 2017
Suzanne L. Topalian, MD

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery, Johns Hopkins Medicine, discusses the impact of anti-PD-1 and anti-PD-L1 agents in the treatment of merkel cell carcinoma.